ORN.F Oryzon Genomics S.A

Healthcare Biotechnology Frankfurt Exchange
2.51 EUR
Close of Nov 13, 2026
2.27 3.33
Market cap
EUR 206M
P/E
-
P/B
1.62x
ROE
-2.3%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is ORN.F undervalued?

Graham number

The Graham number of Oryzon Genomics S.A cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Oryzon Genomics S.A fundamental analysis

No fundamental analysis for Oryzon Genomics S.A yet.

Oryzon Genomics S.A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Oryzon Genomics S.A

Oryzon Genomics S.A., a clinical stage biopharmaceutical company, engages in the discovery and development of epigenetics-based therapeutics for patients with cancer and CNS (central nervous system), oncology, and hematology disorders. Its clinical phase compounds include iadademstat (ORY-1001), a selective LSD1 inhibitor that is in Phase II trials for oncology; and vafidemstat (ORY-2001), a CNS-optimized LSD1 inhibitor, which is in Phase II trials for the treatment of CNS a…

Full company profile